Transfection of Exogenous Fibroblast Growth Factor (FGF) on Human Embryonic Stem Cells (ESCs) as a Regenerative Agent for Patients with Type 1 Diabetes Mellitus (T1DM)

Nolan, John; Wijaya, Audrey; Lianto, Agatha; Saraswati, Made

doi:10.30491/ijmr.2020.219730.1077

Transfection of Exogenous Fibroblast Growth Factor (FGF) on Human Embryonic Stem Cells (ESCs) as a Regenerative Agent for Patients with Type 1 Diabetes Mellitus (T1DM)

Document Type : Narrative Review

Authors

John Nolan ¹

Audrey Wijaya ¹

Agatha Lianto ¹

Made Saraswati ²

¹ Medical Faculty of Udayana University, Denpasar, Bali, Indonesia

² Endocrinology and Metabolism Division, Department of Internal Medicine, Medical Faculty of Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia

10.30491/ijmr.2020.219730.1077

Abstract

Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder which results in the INS pancreatic β-cell destruction and contributes to around 5 to 10% of all diabetes mellitus cases, especially in children. At the moment, the only treatment for T1DM is by insulin injection, which is injected in order to prevent the complication of T1DM. However, several studies have shown that combination between Embryonic Stem Cells (ESCs) and the Fibroblast Growth Factor 2 (FGF-2) may be a successful modality to treat T1DM. Actually, the ESCs may become the potential therapy in treating T1DM.

Keywords

Type 1 Diabetes Mellitus

Embryonic Stem Cells

Fibroblast Growth Factor-2